Teva’s stock price isn’t just “down.” It’s just about down to the levels it saw on the last day of Jeremy Levin’s chief exec stint in 2014. And some are wondering just how responsible current CEO Erez Vigodman is for the decline.
Vigodman, of course, got credit for previously sending shares up by 40%, Israeli newspaper Globes points out; they peaked in the summer of 2015, when Teva announced its $40 billion acquisition of Allergan’s generics unit.
Since then, though, things have changed. For one, investor sentiment has soured on the Allergan deal, which now looks as though it may have been overpriced. “At $40 billion, could Teva not have bought businesses with higher profit margins?” one industry source asked Globes.
Then there’s Teva’s other recent M&A move–a buy of Mexico’s Rimsa that went so wrong that Rimsa’s founders sued the company. The lawsuit accuses Teva of concocting false accusations of fraud to wriggle out of the deal. (Teva, for its part, says it was misled and that Rimsa itself committed violations.)
Fair or not, “some investors are connecting the two things,” Leader Capital Markets analyst Sabina Podval Levy told the publication–and they’re worried about a problem with Teva’s M&A engine.
The way Teva sees it, under Vigodman’s leadership, “we have delivered on our promises and continued to execute a growth strategy that we believe will deliver value for patients and shareholders alike,” a spokeswoman told FiercePharma via email.
And as Globes points out, two of the biggest factors affecting Teva’s stock are out of Vigodman’s control. Price erosion is hurting the entire generics industry, and generics challengers are taking on star product Copaxone in a court battle analysts widely expect Teva to lose.
So what can Vigodman do to restore the faith in the meantime? Give the market a signal that Teva knows what it’s doing, Globes suggests, whether it’s a plan for Actavis cost-cutting that will justify the deal price, proof that the Rimsa debacle was a one-time blip, or–perhaps most importantly–evidence that Teva’s skipper is in control of what goes down at the drugmaker.
By Carly Helfand
Source: Fierce Pharma
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
